Date
15 February 2021
Rättvis tillgång på läkemedel bidrar till hållbar tillväxt
In this article in Swedish newspaper Aktuell Hållbarhet, institutional investors Alecta and SEB Investment Management outline their engagement with companies included in the Access to Medicine Index.
Since 2019, in accordance with the UN’s Sustainable Development Goal 3 (Good Health and Wellbeing), Alecta and SEB Investment Management have engaged with and led collaborative investor dialogue with Novo Nordisk, the largest producer of insulin globally, on the company’s performance in the 2021 Access to Medicine Index.
Read the full article here.